OrbusNeich Holds Topping-Out Ceremony for Its Largest R&D and Production Base in Hangzhou

(Hong Kong, October 17, 2025) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929.HK), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, is pleased to announce that a grand topping-out ceremony for its R&D and production base in Fuyang, Hangzhou was held on October 16. This marked the completion of the structural topping out of OrbusNeich’s largest integrated R&D and production facility globally. The facility is expected to secure all relevant permits and commence full production in 2027. By then, the Group’s total annual production capacity will increase by approximately 2.4 million units of balloon and stent products, on top of the current annual production capacity of approximately 2.1 million units.

The Hangzhou base spans a site of around 20,000 m², with a gross floor area above-ground of nearly 60,000 m². The facility will focus on R&D and production of medical devices such as PCI and PTA intervention products, as well as structural heart disease interventional devices. The project represents a total investment of approximately RMB430 million and is equipped with automated production lines to reduce labor costs. Currently, the Group owns more than 250 granted patents and published patent applications, with more than 55 approved products sold in major markets worldwide. Once the Hangzhou base is completed, it will significantly increase the Group’s high-quality production capacity, accelerate the incubation and application of new technologies, enhance the stability of its global supply chain and its overall competitiveness, enabling the Group to seize opportunities from sustainable growth in the global PCI and PTA medical device market.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The establishment of the R&D and production base in Fuyang, Hangzhou, represents a key strategic initiative for OrbusNeich’s future development. The Yangtze River Delta region boasts well-established infrastructure, a strong industrial chain network, and a rich talent pool. These factors make the Hangzhou base a vital hub for enhancing our innovation and production capabilities, supporting our deeper penetration into the PRC market, our expansion across the Asia-Pacific region, as well as further strengthening our global competitiveness.”

With R&D centers, production bases, and logistics hubs in China, Germany, Japan, the Netherlands and other locations, as well as a sales network covering more than 70 countries and regions around the world, OrbusNeich continuously provides doctors with safe, innovative and leading solutions, thereby improving the quality of life for patients with vascular diseases globally. The Hangzhou base will become a key component of this global strategic layout, injecting continuous impetus into the Group’s long-term development.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich (seventh from the left), together with officiating guests, presided over the topping-out ceremony of the Hangzhou base, marking the establishment of a solid strategic pillar for the Group’s future development blueprint.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.